IO Biotech, a clinical-stage biopharmaceutical company, announced on Tuesday that it has signed a clinical trial collaboration and supply agreement with United States-based Merck & Co, Inc, through a subsidiary.
The aim of the partnership is to assess IO Biotech's lead candidate, IO102-IO103, along with KEYTRUDA (pembrolizumab), Merck & Co, Inc's anti-PD-1 (programmed death receptor-1) therapy, in patients with cancer.
The product is an investigational cancer vaccine for which IO Biotech will sponsor the clinical trials.
The proposed Phase three trial will be an open label, randomised clinical trial to assess the combination of IO102-IO103 with MSD's anti-PD-1 therapy, KEYTRUDA, compared to KEYTRUDA alone in patients with earlier untreated, unresectable or metastatic melanoma. Biomarker studies will also be carried out.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study